Evidence map›Paper›PMID 30596402›Full record

Trial reportBritish journal of haematology2018

Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.

Lihua E Budde, David Wu, Daniel B Martin, Mary Philip, Andrei R Shustov, Stephen D Smith, Ted A Gooley, Tara L Chen, Edward N Libby, Eric Y Chen and 5 more

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Lihua E BuddeDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.ORCID 0000-0003-1464-5494
David WuDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Daniel B MartinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mary PhilipDepartment of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA.
Andrei R ShustovDepartment of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA.
Stephen D SmithClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ted A GooleyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Tara L ChenDepartment of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA.
Edward N LibbyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Eric Y ChenGroup Health Permanente, Seattle, WA, USA.
Kiarash KojouriSkagit Valley Hospital Regional Center, Mount Vernon, WA, USA.
Alan LangerakSt. Alphonsus Regional Medical Center, Boise, ID, USA.
Jennifer E RodenDepartment of Medicine, Divisions of Medical Oncology and Hematology, University of Washington, Seattle, WA, USA.
Oliver W PressClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ajay K GopalClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0003-3023-6834
Fred Hutch Cancer Center · USUniversity of Washington Medical Center · USCity of Hope · USGroup Health Cooperative · USSaint Alphonsus Regional Medical Center · USSkagit Valley Hospital · USUniversity of Washington · US

Funding

Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
TREATMENT OF B-CELL LYMPHOMAP01CA044991 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BALDWIN, JANELL · 1988 to 2015
$29.3M
Molecularly Targeted Therapy for LymphomaK24CA184039 · NCI · UNIVERSITY OF WASHINGTON · PI GOPAL, AJAY · 2014 to 2018
$866k
NCI NIH HHS K24 CA184039NCI NIH HHS P01 CA044991NCI NIH HHS P50 CA107399
6 · The paper itself

Abstract

We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)EC) via a multicentre phase I/II study for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and classic Hodgkin lymphoma (HL). Therapy consisted of 60-120 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideCarboplatinDehydrationEtoposideFebrile NeutropeniaFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProspective StudiesRecurrenceRituximabBendamustine HydrochlorideCarboplatinEtoposideRituximabbendamustineclinical triallymphomasalvage regimenstem cell mobilizationTREC

Identifiers

PMID30596402
PMCPMC6314205
OpenAlexW2891826085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.